GlassScriptPhysician profile
Sarah Ruth Goodyear
NPI 1891728622
$5,685.93
in general payments reported to CMS, 2019-2025
62 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $197 · 2021: $609 · 2022: $624 · 2023: $800 · 2024: $1,119 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,422 · Education: $17.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,421.66 |
| Education | $17.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $407.50 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Genzyme Corporation | $338.89 | 2019-2025 | |
| Genentech USA, INC. | $315.60 | 2019-2025 | Polivy, Perjeta, Kadcyla |
| Daiichi Sankyo INC. | $313.29 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Abbvie INC. | $300.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $278.82 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Novartis Pharmaceuticals Corporation | $259.48 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $256.77 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $228.84 | 2019-2025 | Keytruda |
| Amgen INC. | $196.14 | 2021-2023 | Nplate, Vectibix |
| Alexion Pharmaceuticals, INC. | $175.27 | 2022-2025 | Ultomiris |
| Eisai INC. | $159.56 | 2019-2025 | |
| Incyte Corporation | $152.41 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Bayer Healthcare Pharmaceuticals INC. | $129.06 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $126.57 | 2019-2023 | Epkinly, Imbruvica |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Goodyear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.